(MedPage Today) — ORLANDO — In a phase III trial with potential practice-changing implications, the non-covalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in chronic lymphocytic leukemia…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118892
Author :
Publish date : 2025-12-08 19:40:00
Copyright for syndicated content belongs to the linked Source.
